A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum

drug protocol number

CHS1221

drug sponsor

Cristcot HCA LLC

drug study

Hydrocortisone Acetate 90 mg

drug trial site

King Abdulaziz Medical City NG (Jeddah),King Abdulaziz University Hospital (Jeddah),King Fahad Medical City (Riyadh)

drug status

Ongoing

drug phase